| 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk |
84 |
| Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study |
44 |
| Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions |
42 |
| Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries |
34 |
| Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) |
31 |
| The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation |
31 |
| Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease |
29 |
| Identification of circular RNA Hsa_circ_0001879 and Hsa_circ_0004104 as novel biomarkers for coronary artery disease |
27 |
| Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe(-/-) mice |
27 |
| Metabolic products of the intestinal microbiome and extremes of atherosclerosis |
24 |
| The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity |
23 |
| Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an FCS score |
22 |
| Familial hypercholesterolemia treatments: Guidelines and new therapies |
22 |
| CKD, arterial calcification, atherosclerosis and bone health: Interrelationships and controversies |
18 |
| Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials |
18 |
| Aerobic, resistance or combined training: A systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome |
18 |
| Apabetalone downregulates factors and pathways associated with vascular calcification |
18 |
| Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies |
17 |
| Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia |
17 |
| The protective effect of resveratrol on vascular aging by modulation of the renine-angiotensin system |
16 |
| Hyperuricemia and endothelial function: From molecular background to clinical perspectives |
16 |
| Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats |
16 |
| Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease |
16 |
| A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals |
15 |
| Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps |
15 |
| The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis |
15 |
| PCSK9 inhibition and inflammation: A narrative review |
15 |
| Z-Ligustilide protects vascular endothelial cells from oxidative stress and rescues high fat diet-induced atherosclerosis by activating multiple NRF2 downstream genes |
15 |
| Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease |
14 |
| Nicotine-mediated autophagy of vascular smooth muscle cell accelerates atherosclerosis via nAChRs/ROS/NF-kappa B signaling pathway |
14 |
| Reference values for cardiometabolic risk scores in children and adolescents: Suggesting a common standard |
14 |
| Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany |
14 |
| Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol |
14 |
| HEART UK consensus statement on Lipoprotein(a): A call to action |
14 |
| DNA methylation processes in atheosclerotic plaque |
13 |
| In vivo optical coherence tomography imaging and histopathology of healed coronary plaques |
13 |
| Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation |
13 |
| Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries |
13 |
| IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors |
13 |
| Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes |
13 |
| Distinctive molecular signature and activated signaling pathways in aortic smooth muscle cells of patients with myocardial infarction |
13 |
| Long non-coding RNA nuclear-enriched abundant transcript 1 inhibition blunts myocardial ischemia reperfusion injury via autophagic flux arrest and apoptosis in streptozotocin-induced diabetic rats |
13 |
| SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice |
12 |
| Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry |
12 |
| Dietary inflammatory index and cardiometabolic risk in US adults |
12 |
| Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype |
12 |
| AIBP reduces atherosclerosis by promoting reverse cholesterol transport and ameliorating inflammation in apoE(-/-) mice |
12 |
| Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program |
12 |
| Immunologic burden links periodontitis to acute coronary syndrome |
12 |
| Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review |
12 |
